Hercessi
Term · Oncology and biomedicine · MLC-T-ONC-003840
A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Hercessi binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Hercessi is a type of monoclonal antibody and a type of HER2 receptor antagonist. Also called Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, trastuzumab, and Trazimera.
| Identifier | MLC-T-ONC-003840 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Herceptin; Herzuma; Kanjinti; Ogivri; Ontruzant; trastuzumab; Trazimera |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-003840",
"term": "Hercessi",
"field": "Oncology and biomedicine",
"definition": "A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Hercessi binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Hercessi is a type of monoclonal antibody and a type of HER2 receptor antagonist. Also called Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, trastuzumab, and Trazimera.",
"synonyms": [
"Herceptin",
"Herzuma",
"Kanjinti",
"Ogivri",
"Ontruzant",
"trastuzumab",
"Trazimera"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/hercessi/"
}
Record 8,442 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.